

# Joe Yeong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5590011/publications.pdf>

Version: 2024-02-01

90  
papers

4,182  
citations

230014

27  
h-index

156644

58  
g-index

102  
all docs

102  
docs citations

102  
times ranked

7620  
citing authors

#	ARTICLE	IF	CITATIONS
1	Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. <i>Gut</i> , 2022, 71, 226-229.	6.1	109
2	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. <i>Gut</i> , 2022, 71, 1277-1288.	6.1	23
3	SC-MEB: spatial clustering with hidden Markov random field using empirical Bayes. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	44
4	Comparative genomic analyses between Asian and Caucasian prostate cancers in an 80,829 patient cohort.. <i>Journal of Clinical Oncology</i> , 2022, 40, 273-273.	0.8	2
5	Editorial: Multiplex Immunohistochemistry/Immunofluorescence Technique: The Potential and Promise for Clinical Application. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 831383.	1.6	4
6	Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 121-138.	1.1	12
7	Trajectory of immune evasion and cancer progression in hepatocellular carcinoma. <i>Nature Communications</i> , 2022, 13, 1441.	5.8	28
8	A phase 1b study of <scp>OXIRI</scp> in pancreatic adenocarcinoma patients and its immunomodulatory effects. <i>International Journal of Cancer</i> , 2022, , .	2.3	0
9	Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 683-694.	1.8	45
10	Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. <i>Gastric Cancer</i> , 2022, 25, 741-750.	2.7	42
11	Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4026-4026.	0.8	0
12	Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2021, 74, 838-849.	1.8	53
13	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. <i>Nature Communications</i> , 2021, 12, 117.	5.8	34
14	Investigation of a 22-gene genomic classifier (GC) for risk stratification and molecular subtyping in an Asian prostate cancer (PCa) cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 249-249.	0.8	0
15	CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2353-2365.	2.0	13
16	Clinical implications of systemic and local immune responses in human angiosarcoma. <i>Npj Precision Oncology</i> , 2021, 5, 11.	2.3	6
17	Pan-Cancer Analysis of Ligandâ€“Receptor Cross-talk in the Tumor Microenvironment. <i>Cancer Research</i> , 2021, 81, 1802-1812.	0.4	41
18	Targeting Glycolysis in Macrophages Confers Protection Against Pancreatic Ductal Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6350.	1.8	15

#	ARTICLE	IF	CITATIONS
19	Cancer-Testis Antigens in Triple-Negative Breast Cancer: Role and Potential Utility in Clinical Practice. <i>Cancers</i> , 2021, 13, 3875.	1.7	9
20	Comparison between non-pulmonary and pulmonary immune responses in a HIV decedent who succumbed to COVID-19. <i>Gut</i> , 2021, , gutjnl-2021-324754.	6.1	3
21	Non-terminally exhausted tumor-resident memory HBV-specific T <sub>H</sub> cell responses correlate with relapse-free survival in hepatocellular carcinoma. <i>Immunity</i> , 2021, 54, 1825-1840.e7.	6.6	64
22	Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1349-1358.	0.5	48
23	Leveraging advances in immunopathology and artificial intelligence to analyze in vitro tumor models in composition and space. <i>Advanced Drug Delivery Reviews</i> , 2021, 177, 113959.	6.6	7
24	Improving Precision and Implementation of Immuno-Oncology Biomarkers. <i>Journal of Thoracic Oncology</i> , 2021, 16, e91-e93.	0.5	0
25	Biomarkers for Precision Urothelial Carcinoma Diagnosis: Current Approaches and the Application of Single-Cell Technologies. <i>Cancers</i> , 2021, 13, 260.	1.7	14
26	Mass-forming immunoglobulin G4-related disease shows indolent clinical course after surgical resection, clinicopathological analysis of a series of 15 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, , 1.	1.4	0
27	Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 1025-1035.	3.7	56
28	Immune Response in Myocardial Injury: In Situ Hybridization and Immunohistochemistry Techniques for SARS-CoV-2 Detection in COVID-19 Autopsies. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 658932.	1.6	5
29	Immune profiling reveals enrichment of distinct immune signatures in high-risk oral potentially malignant disorders. , 2021, 9, A957-A957.		1
30	Dissecting the spatial heterogeneity of SARS-CoV-2-infected tumour microenvironment reveals a lymphocyte-dominant immune response in a HBV-associated HCC patient with COVID-19 history. , 2021, 9, A656-A656.		0
31	ImmunoAtlas: an online public portal for sharing, visualizing, and referencing multiplex immunohistochemistry/immunofluorescence (mIHC/IF) images and results for immuno-oncology. , 2021, 9, A657-A657.		1
32	Using deep learning approaches with mIF images to enhance T cell identification for tumor-automation of infiltrating lymphocytes (TILs) scoring on H&E images. , 2021, 9, A855-A856.		0
33	The immune marker LAG-3 increases the predictive value of CD38 <sup>+</sup> immune cells for survival outcome in immunotherapy-treated hepatocellular carcinoma. , 2021, 9, A97-A98.		4
34	Epstein-Barr Virus Epithelial Cancers: A Comprehensive Understanding to Drive Novel Therapies. <i>Frontiers in Immunology</i> , 2021, 12, 734293.	2.2	24
35	Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy. <i>JHEP Reports</i> , 2020, 2, 100062.	2.6	42
36	The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy. <i>Cells</i> , 2020, 9, 26.	1.8	29

#	ARTICLE	IF	CITATIONS
37	Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. , 2020, 8, e000987.		70
38	Transcriptional Spatial Profiling of Cancer Tissues in the Era of Immunotherapy: The Potential and Promise. Cancers, 2020, 12, 2572.	1.7	38
39	The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research. SLAS Technology, 2020, 25, 522-544.	1.0	18
40	Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients. Breast Cancer Research, 2020, 22, 42.	2.2	20
41	Digital spatial profiling application in breast cancer: a user's perspective. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 885-890.	1.4	16
42	Counting Mitoses With Digital Pathology in Breast Phyllodes Tumors. Archives of Pathology and Laboratory Medicine, 2020, 144, 1397-1400.	1.2	5
43	Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers. Breast Cancer Research and Treatment, 2020, 180, 369-377.	1.1	33
44	Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC. Journal of Clinical Pathology, 2020, 73, 557-562.	1.0	53
45	Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer. Journal of Clinical Pathology, 2020, 73, 147-153.	1.0	7
46	Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy. Cancers, 2020, 12, 1025.	1.7	30
47	Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Communications, 2020, 40, 135-153.	3.7	339
48	Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer. Frontiers in Immunology, 2020, 11, 615091.	2.2	28
49	Partial absence of PD-1 expression by tumor-infiltrating EBV-specific CD8 <sup>+</sup> T cells in EBV-driven lymphoepithelioma-like carcinoma. Clinical and Translational Immunology, 2020, 9, e1175.	1.7	7
50	Genomic landscape of lung adenocarcinoma in East Asians. Nature Genetics, 2020, 52, 177-186.	9.4	281
51	PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas. Journal of Clinical Pathology, 2020, 73, 463-469.	1.0	5
52	Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. Journal of Clinical Investigation, 2020, 130, 5833-5846.	3.9	58
53	A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678.. Journal of Clinical Oncology, 2020, 38, 4590-4590.	0.8	33
54	A prospective observational study of combinatorial abiraterone (AA) and radical radiotherapy (RT) in node-positive (N+) prostate cancer (PCa).. Journal of Clinical Oncology, 2020, 38, e17555-e17555.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience. <i>World Journal of Clinical Oncology</i> , 2020, 11, 283-293.	0.9	2
56	Preliminary outcomes of a prospective observational study of combinatorial abiraterone acetate/enzalutamide (AA/Enz) and radical radiotherapy (RT) in nonmetastatic node-positive (N+M0) prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2020, 38, 227-227.	0.8	0
57	825â€¦Deep immune profiling of SARS-CoV-2 associated immune microenvironment in cancer tissues from recovered COVID-19 patients. , 2020, , .		0
58	475â€¦Incidental finding of colorectal cancer in a COVID-19 patient, followed by deep profiling of SARS-CoV-2-associated immune landscape and tumour microenvironment. , 2020, , .		0
59	Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. <i>Gut</i> , 2019, 68, 916-927.	6.1	228
60	Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 295-305.	1.1	12
61	Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2019, 10, 2093.	2.2	51
62	Prognostic role of immune infiltrates in breast ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 17-27.	1.1	40
63	Pan-cancer analysis connects tumor matrisome to immune response. <i>Npj Precision Oncology</i> , 2019, 3, 15.	2.3	58
64	Role of tissue resident memory CD8+ T cells in triple negative breast cancer. <i>Pathology</i> , 2019, 51, S98.	0.3	0
65	Prognostic value of CD8â€‰%+â€‰%PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. , 2019, 7, 34.		75
66	Hepatitis B virus-Associated Intrahepatic Cholangiocarcinoma Has Distinct Clinical, Pathological and Radiological Characteristics: A Systematic Review. <i>Surgery, Gastroenterology and Oncology</i> , 2019, 24, 5.	0.0	2
67	Genomic and immune infiltration differences between MSI and MSS GI tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 528-528.	0.8	0
68	A novel computational OMICS and non-OMICS approach for identifying true pathogenic risk variants for Asian prostate cancer.. <i>Journal of Global Oncology</i> , 2019, 5, 47-47.	0.5	0
69	An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use. <i>Pathology</i> , 2018, 50, 333-341.	0.3	65
70	Caveolin-1 expression as a prognostic marker in triple negative breast cancers of Asian women. <i>Journal of Clinical Pathology</i> , 2018, 71, 161-167.	1.0	23
71	An integrated automated multispectral imaging technique that simultaneously detects and quantitates viral RNA and immune cell protein markers in fixed sections from Epstein-Barr virus-related tumours. <i>Annals of Diagnostic Pathology</i> , 2018, 37, 12-19.	0.6	20
72	Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. <i>Nature</i> , 2018, 557, 575-579.	13.7	942

#	ARTICLE	IF	CITATIONS
73	High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 1209.	2.2	114
74	RNA-Seq analyses of immune cell-type enrichments in 158 Asian colorectal cancers (CRCs).. <i>Journal of Clinical Oncology</i> , 2018, 36, e15597-e15597.	0.8	1
75	A phase II open-label, single-centre, non-randomized trial of Y90 transarterial radioembolization in combination with nivolumab in Asian patients with intermediate stage hepatocellular carcinoma: An immunological study of radioembolization in combination with anti-PD1 therapy in HCC.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS542-TPS542.	0.8	7
76	Using computer assisted image analysis to determine the optimal Ki67 threshold for predicting outcome of invasive breast cancer. <i>Oncotarget</i> , 2018, 9, 11619-11630.	0.8	11
77	Abstract 5725: Systematic identification of tumour-specific neoantigens (by whole-genome sequencing) and correlation between tumour neoantigen burden, PD-L1 expression and immune infiltrates in 158 Asian colorectal cancers. , 2018, , .		1
78	TFE3-Expressing Epithelioid Rich Perivascular Epithelioid Cell Neoplasm (PEComa) of the Bladder with Unusual Benign Course. <i>Annals of Clinical and Laboratory Science</i> , 2018, 48, 110-115.	0.2	8
79	Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. <i>Gut</i> , 2017, 66, 342-351.	6.1	359
80	Upregulation of hydroxysteroid sulfotransferase 2B1b promotes hepatic oval cell proliferation by modulating oxysterol-induced LXR activation in a mouse model of liver injury. <i>Archives of Toxicology</i> , 2017, 91, 271-287.	1.9	21
81	Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 21-35.	1.1	102
82	A functional SNP associated with atopic dermatitis controls cell type-specific methylation of the VSTM1 gene locus. <i>Genome Medicine</i> , 2017, 9, 18.	3.6	30
83	Cleason grade grouping of prostate cancer is of prognostic value in Asian men. <i>Journal of Clinical Pathology</i> , 2017, 70, 745-753.	1.0	12
84	Identifying progression predictors of breast ductal carcinoma in situ. <i>Journal of Clinical Pathology</i> , 2017, 70, 102-108.	1.0	29
85	A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinoma. <i>Pathology</i> , 2017, 49, 786-789.	0.3	13
86	Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 237-247.	1.1	122
87	The role of nuclear factor-kappa B and endoplasmic reticulum stress in hepatitis B viral-induced hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2016, 5, S13-S17.	0.4	1
88	Approaches for Handling Immunopathological and Clinical Data Using Deep Learning Methodology: Multiplex IHC/IF Data as a Paradigm. , 0, , .		0
89	A Phase II Trial of Y90-Resin Microspheres Radioembolization Followed by Nivolumab in Advanced Hepatocellular Carcinomaâ€ CA 209-678. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
90	Distinct Tumor-Resident Memory HBV-Specific T Cell Responses Correlate with Relapse-Free Survival in Patients with HBV-Associated Hepatocellular Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0